中国·腾博-www.tengbo9885.com|官网首发

中文
中文

以患者需求为核心,驱动细胞免疫治疗创新,实现癌症可控化并最终治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.

2018
  • 0
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 
Nat Commun. 9(1):5361. (*: Corresponding authors, PMCID: PMC6299138)
Jia Q., Wu W., Wang Y., Alexander P.B., Sun C., Gong Z., Cheng J., Sun H., Guan Y., Xia X., Yang L., Yi X., Wan Y., Wang H., Futreal P.A., Li Q.-J.*, Zhu B.* (2018)


Late-stage tumors induce anemia and immunosuppressive extramedullary erythroid progenitor cells.
Nature Medicine 24(10):1536-1544 (*: Corresponding authors, PMCID: PMC6211844)
Zhao L., He R., Long H., Guo B., Jia Q., Qin D., Liu S.-Q., Wang Z., Xiang T.,  Zhang J., Tan Y., Huang J., Chen J., Wang F., Xiao M., Gao J., Yang X., Zeng H., Wang X., Hu C., Alexander P. B., Symonds A.L.J.,  Yu J., Wan Y., Li Q.-J.*, Ye L.*, Zhu B.* (2018) 


03.23
2022
来源:
关键词:
相关阅读
关于腾博tengbo9885官网
研究与发展
产品及临床
新闻与媒体
XML 地图